Related Experiment Video
Updated: Aug 8, 2026
10:04
The Aortic Ring Co-culture Assay: A Convenient Tool to Assess the Angiogenic Potential of Mesenchymal Stromal Cells In Vitro
Published on: September 18, 2017
Translating angiogenesis research into the clinic: the challenges ahead
1Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, D-79106 Freiburg, Germany. augustin@angiogenese.de
The British Journal of Radiology
|October 1, 2004
Summary
Angiogenesis research shows promise for treating tumors and diseases like macular degeneration. However, understanding tumor neovasculature and reliable biomarkers for anti-angiogenic therapies remains a challenge.
Area of Science:
- Biomedical Sciences
- Vascular Biology
- Oncology
Background:
- Angiogenesis research is a rapidly growing field with significant therapeutic potential.
- Anti-angiogenesis strategies are being developed for tumors and non-oncological diseases.
- Molecular determinants of angiogenesis are increasingly understood.
Purpose of the Study:
- To review the current understanding of tumor vasculature.
- To discuss challenges in translating angiogenesis research into clinical practice.
- To identify key unanswered questions in anti-angiogenic therapy.
Main Methods:
- Literature review of angiogenesis biology.
- Analysis of current concepts in tumor neovasculature.
- Discussion of clinical trial parameters and biomarker development.
Main Results:
- Significant progress has been made in understanding the angiogenic cascade.
- Numerous angiomodulatory compounds are in clinical trials, including anti-VEGF therapies.
- Despite progress, knowledge of human tumor neovasculature is limited.
Conclusions:
- Translating angiogenesis research into effective clinical therapies faces hurdles.
- Lack of angiogenesis-related parameters in clinical trials hinders efficacy assessment.
- Development of reliable biomarkers is crucial for advancing anti-angiogenic treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...